Confirm candidacy
Confirm whether you are a candidate for cytoreductive surgery with HIPEC.
Specialized Unit
Surgery for Gastric Carcinomatosis
At Quenet-Torrent Institute, we treat peritoneal carcinomatosis of gastric origin with cytoreductive surgery and HIPEC in carefully selected patients, always within a multidisciplinary context.
CONTACT SPECIALISTNeed to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon
-
EXTENSIVE EXPERIENCE +20,000 surgeries performed
-
LATEST TECHNOLOGY in surgical strategy
-
PERSONALIZED CARE First contact within 24/48h
What is gastric carcinomatosis?
Gastric carcinomatosis is the spread of gastric cancer cells to the peritoneum. It is one of the most common forms of gastric cancer progression and has traditionally been considered a terminal condition.
However, advances in multimodal treatment have shown that in carefully selected patients, the combination of cytoreductive surgery and HIPEC can significantly improve survival and even offer cure potential in limited cases.
Strict patient selection is key. Results depend on the extension of peritoneal disease, response to systemic treatment, and achievability of complete cytoreduction.
Why request a second opinion for gastric carcinomatosis?
Requesting a second opinion can reveal treatment options not initially considered.
Evaluate response
Evaluate response to systemic chemotherapy and surgical options.
Compare approaches
Compare the palliative approach with potentially curative options in specialized centers.
Clinical trials
Consider participation in clinical trials with innovative treatments.
A specialized evaluation can change the prognosis in selected patients.
How do we treat gastric carcinomatosis?
Treatment in selected cases combines systemic chemotherapy with locoregional surgery.
Neoadjuvant chemotherapy
Systemic treatment to evaluate response and select candidates.
Cytoreductive surgery
Complete removal of visible disease when feasible.
HIPEC
Hyperthermic intraperitoneal chemotherapy to treat microscopic residual disease.
Prophylactic HIPEC
In selected cases at high risk of peritoneal recurrence.
Patient selection is strict and based on multiple clinical and pathological factors.
Our Technology
Technology for treating gastric carcinomatosis
Advanced technology helps in patient selection and surgical precision.
Staging laparoscopy
Peritoneal Cancer Index evaluation and resectability assessment.
PET-CT
Detection of extra-abdominal disease that would contraindicate surgery.
Automated HIPEC equipment
Precise thermal and flow control during perfusion.
Multidisciplinary team
Patient discussion in specialized tumor board.
WHY CHOOSE US?
Experience in complex cases
Quenet-Torrent Institute offers a comprehensive approach, with teams specialized in advanced peritoneal disease.
Complex Case Experience
We specialize in treating advanced and metastatic cancer, using complex and innovative techniques that other teams don't offer.
Comprehensive Multidisciplinary Approach
We form a team around you with surgeons, oncologists, radiologists, nutritionists, and psychologists, all working together for your cure.
Research Advances
We stay up-to-date with the latest scientific advances, allowing us to apply innovative treatments with better results.
State-of-the-Art Technology
We have facilities equipped with the most advanced medical technology, allowing us to perform high-precision procedures with less impact on the body.
Personalized and Close Care
We care about each patient as a person. We listen, support, and guide at every step of the way.
Our Team
Gastric carcinomatosis specialists
Every physician at Quenet-Torrent Institute is a recognized expert in their field, committed to each patient's well-being.
Dr. François Quenet
Oncological Surgeon
View doctor"Internationally renowned surgeon, expert in gastrointestinal and hepatobiliary tumors. Recognized for his precision in highly difficult surgeries."
Dr. Juan José Torrent
Oncological Surgeon
View doctor"Specialist in gynecological tumors and peritoneal carcinomatosis. A reference in complex and personalized oncological surgery."
Frequently asked questions about gastric carcinomatosis
Answers to the most common questions about diagnosis, treatment, and prognosis.
Can gastric carcinomatosis be cured?
In very selected cases with limited disease and good response to chemotherapy, long-term survival is possible.
Who is a candidate for surgery?
Patients with limited peritoneal disease, good general condition, and favorable response to systemic treatment.
What is prophylactic HIPEC?
Application of HIPEC at the time of gastrectomy in patients at high risk of peritoneal recurrence.
How long is the recovery?
Hospitalization is usually 10-14 days and complete recovery 2-3 months.
Is a second opinion necessary?
Always recommended to confirm whether you are a candidate for surgical treatment.
Where can I receive this treatment safely?
In specialized centers with experience in peritoneal surface malignancies, like Quenet-Torrent Institute.
Easy Contact
Need to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon.